Cytori Therapeutics, Inc.

Annual Shareholder Meeting

August 16, 2012

9:00 AM PT

Safe Harbor Statement

This presentation may contain certain ‘forward-looking statements’. All

statements, other than statements of historical fact, that address activities, events

or developments that we intend, expect, project, believe or anticipate will or

may occur in the future are forward-looking statements. Such statements are

based upon certain assumptions and assessments made by our management in

light of their experience and their perception of historical trends, current

conditions, expected future developments and other factors they believe to be

appropriate.

The forward-looking statements included in this presentation are also subject to a

number of material risks and uncertainties. We caution investors not to place

undue reliance on the forward-looking statements contained in this presentation.

We would advise reading our annual report filed with the United States Securities

and Exchange Commission on Form 10-K for a more detailed description of these

risks.

Our Company Mission

To improve the quality and length of life

by providing innovative cell therapy products

CYTORI - The Leader in Cell Therapy

Lesley’s Story

Pre-Treatment Adjunct to Burn Resurfacing

Pre-Treatment

Lesley’s Story

Pre-Treatment

3 Weeks Post Treatment 8 Weeks Post Treatment 20 Weeks Post Treatment

Lesley’s Story

Pre-Treatment Burn Scar Repair

Pre-Treatment

18 Months

Lesley’s Story

Pre-Treatment Burn Scar Repair

Pre-Treatment

Before

18 Months

Lesley’s Story

Pre-Treatment 12 Month Post Op 18 Month Post Op

Easy to Access Cells

A small amount of fat is removed (about half a can of coke)

Point-of-Care

Your tissue is processed right at the side of your bed

About an hour …

And available when you need it

The Power of Cell Therapy

> 5,000 patients have been treated

using their own cells with Cytori products

Clinical Leadership

11%

53%

27%

1%

1% 2%

5%

> 5,000 Patients Treated (est.)

Breast Recon

Breast Augmentation

Other Fat Grafting

Cardiac

Urology

5 Clinical Trials • 3 Complete (2 CV, 1 Breast)

• 2 Ongoing (2 CV)

• Others planned

40+ Investigator Studies

>5,000 patients treated

Available in 47 countries

>8,600 patients treated

Available in 52 countries

Available globally

Cytori Product Families

Momentum is Building

Expanded soft tissue claims Recurring revenues increasing Preparing for vascular market Demand for cell & tissue banking is increasing

Preclinical Research Phase I/II Pivotal Full Market Access Private Pay/ Reimbursement

Breast /Buttock Face Augmentation

Breast Cancer Reconstruction

Soft Tissue Facial Wasting

Diabetic Foot Ulcers

Fistula

Burns

Radiation Induced Injury

SUI

Sports Related Injury

Heart Failure / No Option Chronic Myocardial Ischemia

Acute Myocardial Infarction

Critical Limb Ischemia

Puregraft

Banking

Advance Pipeline toward Market Access

Refractory Heart Failure

Emerson Perin, MD Texas Heart Institute

ATHENA TRIAL • FDA Approved Multicenter Trial • Double Blind, Placebo controlled • 45 Patients: 30 ADRC, 15 Placebo • 6 Leading US Cardiac Cell Therapy Centers

Dr. Perin, Dr. Willerson, Texas Heart Dr. Henry, Minneapolis Heart Dr. Miller, University South Florida Dr. Pepine, University of Florida, Gainsville Dr. Mendelsohn, Cardiology PC, Alabama Dr. Schatz, Scripps La Jolla, California

Acute Heart Attack

Eric Duckers, MD, PhD Rotterdam, The Netherlands

ADVANCE TRIAL • European Pivotal Trial • Prospective • Randomized (2:1) • Double Blind • Placebo controlled • Up to 216 patients for STEMI • Enrollment to begin in Q4 ’12

• G5 • The Netherlands • Canada • Poland

Intellectual Property

• 51 Patents + 2 Allowances

• 75+ Applications in process

• ~50% growth in portfolio

• Avg 1 patent / month

Shareholder Value

• Advance pipeline toward Market Access

• Manage to cash flow positive Grow revenue Control costs

• Strengthen balance sheet

Milestones Achieved in 2012

FDA approval to initiate ATHENA

CE Mark for wounds, burns, radiation, ischemia

Additional country approvals (Russia, Croatia)

Breast Reconstruction Reimbursement filing - UK

Publish 6 & 18 month data: APOLLO

Publish 12 month data: RESTORE 2

Puregraft 850 FDA & CE Mark, PG250 approvals

Grow IP Portfolio > 15%

Milestones

• Establish Strategic Partnership

• Initiate ATHENA Trial – US (First patient enrolled)

• Cardiovascular CE Mark expansion

• Additional country approvals

(Canada, Australia, New Zealand, Japan)

• FDA Appeal Resolution

• Publish 18 month data – PRECISE Trial

• Revenue growth target of $9 million

Vision

Cells concentrated from

a person’s own fat tissue, will be used to treat

a broad array of diseases in patients around the world

MISSION: To improve the quality and length of life

by providing innovative cell therapy products

Cytori is…

Defining the market for point-of-care cell therapy Delivering on the promise in cell therapy Leading in delivering cell therapy to doctors & patients

MISSION: To improve the quality and length of life

by providing innovative cell therapy products

Thank You !

Cytori: Restoring Lives